Search

Novo Nordisk A-S (Class B)

Uždarymo kaina

341.35 -0.28

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

340.8

Max

343.3

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.5B

27B

Pardavimai

-1.2B

77B

P/E

Sektoriaus vid.

14.432

37.461

Pelnas, tenkantis vienai akcijai

5.96

Dividendų pajamingumas

3.4

Pelno marža

34.484

Darbuotojai

78,387

EBITDA

44B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+9.53% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.40%

2.33%

Kitas uždarbis

2025-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

138B

1.5T

Ankstesnė atidarymo kaina

341.63

Ankstesnė uždarymo kaina

341.35

Novo Nordisk A-S (Class B) Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-17 10:26; UTC

Pagrindinės rinkos jėgos

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

2025-10-17 10:25; UTC

Pagrindinės rinkos jėgos

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

2025-10-15 15:36; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

2025-10-15 13:27; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

2025-10-09 10:49; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

2025-10-01 08:54; UTC

Pagrindinės rinkos jėgos

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

2025-10-22 10:45; UTC

Uždarbis

AI Stocks Aren't the Only Market Play. How -2-

2025-10-22 10:45; UTC

Uždarbis

AI Stocks Aren't the Only Market Play. How Earnings Are Easing Recession Fears. -- Barrons.com

2025-10-17 10:10; UTC

Pagrindinės rinkos jėgos

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

2025-10-15 12:33; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

2025-10-15 12:32; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

2025-10-15 12:32; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

2025-10-15 12:32; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

2025-10-10 16:19; UTC

Įsigijimai, susijungimai, perėmimai

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

2025-10-10 13:03; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Novo Nordisk's Akero Deal Makes Sense But Raises Questions -- Market Talk

2025-10-09 15:17; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk Is Buying Akero Therapeutics. It's More Good News for Biotech Stocks. -- Barrons.com

2025-10-09 11:31; UTC

Įsigijimai, susijungimai, perėmimai

Akero Therapeutics Stock Soars. Novo Nordisk Is Buying the Biotech for up to $5.2 Billion. -- Barrons.com

2025-10-09 10:34; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2B

2025-10-09 10:07; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk Says Metabolic Dysfunction-Associated Steatohepatitis is Closely Linked With Diabetes and Obesity

2025-10-09 10:05; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk: Akero is Developing Treatment For Liver Disease Metabolic Dysfunction-Associated Steatohepatitis

2025-10-09 10:04; UTC

Įsigijimai, susijungimai, perėmimai

Akero: Each CVR to Entitle Holder to Cash Payment of $6/Shr Upon Full U.S. Regulatory Approval of Efruxifermin for Treatment of Compensated Cirrhosis Due to MASH by June 30, 2031 >AKRO

2025-10-09 10:03; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk To Buy Akero Therapeutics for $4.7B in Cash, Plus Potentially an Additional $500M

2025-10-09 10:01; UTC

Įsigijimai, susijungimai, perėmimai

Novo Nordisk Agrees to Buy Akero Therapeutics For $54 a Share

2025-10-07 09:15; UTC

Rinkos pokalbiai

Novo Nordisk Consensus 2027 Sales Expectations Look Too High -- Market Talk

2025-10-01 09:05; UTC

Karštos akcijos

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

2025-09-29 12:04; UTC

Rinkos pokalbiai

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

2025-09-22 13:43; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

2025-09-18 12:30; UTC

Rinkos pokalbiai

Correction to Novo Nordisk Market Talk

2025-09-18 12:00; UTC

Rinkos pokalbiai

Novo Nordisk's Prospects Could Turn Around -- Market Talk

2025-09-18 08:55; UTC

Karštos akcijos

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

Novo Nordisk A-S (Class B) Prognozė

Kainos tikslas

By TipRanks

9.53% į viršų

12 mėnesių prognozė

Vidutinis 1,162.73 DKK  9.53%

Aukščiausias 1,550 DKK

Žemiausias 720 DKK

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Novo Nordisk A-S (Class B) kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

7

Pirkti

2

Laikyti

2

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat